Treats T-cell acute lymphoblastic leukemia (T-ALL) and … lymphoblastic lymphoma (T-LBL). ANDA 214809, held by Shorla. Nelarabine.
As of Nov 14, 2026, ANDA 214809 (Nelarabine), held by Shorla, was first approved by FDA on Mar 3, 2023, with 0 approved supplements and 0 published complete response letters.
Nelarabine Injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least 2 chemotherapy regimens. Nelarabine Injection is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) and T cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 3, 2023 | Original application | Approved | None posted |
| Nelarabine250MG/50ML (5MG/ML) · injectable;intravenous | Nelarabine | Rx |
| Nelarabine375MG/75ML (5MG/ML) · injectable;intravenous | Nelarabine | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
